ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
Exploratory analysis from a Phase 1b/2 trial showed that evorpacept combined with zanidatamab achieved a 100% objective response rate in HER2-positive breast cancer patients with high CD47 expression. Median progression-free survival in this biomarker-selected group was 22.1 months, significantly outperforming the 3.4 months seen in patients with low CD47 expression.
Key figures
- Drug Name
- evorpacept
- Phase Of Trial
- Phase 1b/2
- Overall c ORR
- 33% (n=24)
- Overall m PFS
- 3.6 months
- C ORR low cd47
- 25% (n=1/4)
- M PFS low cd47
- 3.4 months
- C ORR high cd47
- 100% (n=5/5)
- M DOR high cd47
- 20.2 months
- M PFS high cd47
- 22.1 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.